1-7 of 7
Liang Han
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT008: First-in-human study of SYS6010, a novel EGFR targeting antibody drug conjugate (ADC) for patients with advanced solid tumors

Free
Shun Lu, Zhen Zhou, Zi-Ming Li, Zhi-Yong HE, Jian Fang, Hong-Mei Sun, Yi Gong, Ying Cheng, Yi-Bing LIU, Yu Yao, Yan Yu, Yan-Hong Shang, Xiang-Lin Yuan, Liang Han, Mingjun Zhang, Kun-Yu Yang, Liqiong Zhang, Xuechao Wan, Huanhuan Qi, Yang Yang
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT008.
https://doi.org/10.1158/1538-7445.AM2025-CT008
Published: 25 April 2025
View articletitled, Abstract CT008: First-in-human study of SYS6010, a novel EGFR targeting antibody drug conjugate (ADC) for patients with advanced solid tumors
Journal Articles

Abstract CT138: Safety and efficacy of HS-10370 in KRAS G12C-mutated advanced solid tumors: Updated results from phase 1 study

Free
Xiangjiao Meng, Yan Zhang, Yan Wang, Liang Han, Jianhua Chen, Qiming Wang, Zhong Lin, Shujun Feng, Zhenzhong Su, Xiaoqing Zhang, Xiaorong Dong
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_2): CT138.
https://doi.org/10.1158/1538-7445.AM2025-CT138
Published: 25 April 2025
View articletitled, Abstract CT138: Safety and efficacy of HS-10370 in KRAS G12C-mutated advanced solid tumors: Updated results from phase 1 study
Journal Articles

Abstract CT119: Safety and efficacy of HS-10370 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)

Free
Xiaorong Dong, Xiangjiao Meng, Yan Zhang, Yan Wang, Jianhua Chen, Liang Han, Qiming Wang, Zhong Lin, Hongying Wei, Siheng Lin, Chuan Li, Qiong Wu
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT119.
https://doi.org/10.1158/1538-7445.AM2024-CT119
Published: 05 April 2024
View articletitled, Abstract CT119: Safety and efficacy of HS-10370 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)
Journal Articles

Abstract 6390: Exploratory biomarker analysis of phase 3 ASTRUM-005 study: Serplulimab versus placebo plus chemotherapy for extensive-stage small cell lung cancer

Free
Ying Cheng, Liang Han, Lin Wu, Jun Chen, Hongmei Sun, Guilan Wen, Yinghua Ji, Anastasia Zimina, Jianhua Shi, Zhijie Pan, Jinsheng Shi, Xicheng Wang, Fang Yang, Xinyi Yang, Mengkai Chen, Shiqi Zhong, Qingyu Wang, Jing Li, Jiancheng Cheng, Chen Ling, Yongqiang Shan, Jun Zhu, The ASTRUM-005 Study Group
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 6390.
https://doi.org/10.1158/1538-7445.AM2024-6390
Published: 22 March 2024
View articletitled, Abstract 6390: Exploratory biomarker analysis of phase 3 ASTRUM-005 study: Serplulimab versus placebo plus chemotherapy for extensive-stage small cell lung cancer
Journal Articles

Abstract CT201: HS-10365, a highly potent and selective RET tyrosine kinase inhibitor, demonstrates robust activity in RET fusion positive NSCLC patients

Free
Shun Lu, Qiming Wang, Lin Wu, Ligang Xing, Yintao Li, Liang Han, Xiaorong Dong, Hongying Wei, Wen Xu, Chuan Li, Liuqing Yang, Qiong Wu
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT201.
https://doi.org/10.1158/1538-7445.AM2023-CT201
Published: 14 April 2023
View articletitled, Abstract CT201: HS-10365, a highly potent and selective RET tyrosine kinase inhibitor, demonstrates robust activity in RET fusion positive NSCLC patients
Journal Articles

MNX1-AS1 Promotes Phase Separation of IGF2BP1 to Drive c-Myc–Mediated Cell-Cycle Progression and Proliferation in Lung Cancer

Available to Purchase
Qingqing Zhu, Chongguo Zhang, Tianyu Qu, Xiyi Lu, Xuezhi He, Wei Li, Dandan Yin, Liang Han, Renhua Guo, Erbao Zhang
Journal: Cancer Research
Cancer Res (2022) 82 (23): 4340–4358.
https://doi.org/10.1158/0008-5472.CAN-22-1289
Published: 02 December 2022
View articletitled, MNX1-AS1 Promotes Phase Separation of IGF2BP1 to Drive c-Myc–Mediated Cell-Cycle Progression and Proliferation in Lung Cancer
Open the PDF for MNX1-AS1 Promotes Phase Separation of IGF2BP1 to Drive c-Myc–Mediated Cell-Cycle Progression and Proliferation in Lung Cancer in another window
Includes: Multimedia, Supplementary data
Journal Articles

Abstract 670: Targeting PI3K/mTOR leads to MEK/ERK over-activation in pancreatic cancer through suppression of mTORC2

Free
Heloisa P. Soares, Ming Ming, Michelle Mellon, Steven H. Young, Liang Han, James Sinnet-Smith, Enrique Rozengurt
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 670.
https://doi.org/10.1158/1538-7445.AM2015-670
Published: 01 August 2015
View articletitled, Abstract 670: Targeting PI3K/mTOR leads to MEK/ERK over-activation in pancreatic cancer through suppression of mTORC2